With continued investment and growing buzz from the industry, the AI hype is expected to extend through 2025 and beyond.

Target-guided synthesis (TGS) is an innovative approach in drug discovery that focuses on the direct interaction between a biological target and small molecule fragments. This method allows ...

Functional genomics can help deconvolute the link between genotype and phenotype in disease, revealing new drug targets and ...

Discover key considerations for executing workflows in drug discovery, from defining research questions and generating ...

With the use of deep learning and advanced algorithms, generative AI can promote acceleration in the design and development ...

Cofounded by Dr. Siddhartha Mukherjee and Reid Hoffman, Manas AI leverages proprietary AI, generative computational chemistry ...

Further, this segment is classified into drug discovery target identification & validation lead identification & optimization de novo drug design. Some other major drivers for the drug discovery ...

Rancho BioSciences, the premier tech-enabled data science partner for biopharma, headquartered in San Diego, California, is ...

Orphan drugs offer critical treatment options for rare diseases, improving quality of life for underserved patients and ...

Insilico Medicine (“Insilico”), a clinical stage generative artificial intelligence (AI)-driven biotechnology company has ...

Quantum computing and artificial intelligence (AI) can be combined with classical computing methods to design and discover small-molecule candidates that target the cancer-driving KRAS protein, ...

Rancho Biosciences will leverage its expertise in subject matter expert data processing and curation to prepare a wide range of life science datasets-including clinical, single cell, spatial, genomic, ...